Ipamorelin
OtherAlso known as NNC 26-0161
Evidence tier
Multiple human trials
3 human trials
- Researched since
- 1998
- Publications
- 53
- Mean purity
- 99.7%
- Vendors listing
- 26
Modern Aminos shows the highest mean assayed purity for Ipamorelin at 99.9% across 2 lot records. Purity figures below come from the certificates named in each row.
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 1998 — 28 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
53 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
Mean assayed purity 99.7% across 26 certificates
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
±0.22 pts purity across lots, mean label deviation 10.2%
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
26 of 26 listing vendors publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
24 of 26 certificates from a recognised independent lab
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is Ipamorelin?
A synthetic pentapeptide that acts as a growth hormone secretagogue in published preclinical work. Supplied as a lyophilised powder.
Studied in published research for growth-hormone release, recovery and body composition.
Regulatory status
Labeled by vendors for laboratory research use only. Not an approved medicine.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
The published literature is mainly preclinical, with a small number of early-phase human studies that were not carried forward to approval. No approved product exists.
- Ipamorelin, the first selective growth hormone secretagogue — European journal of endocrinology (1998)
Peer-reviewed article indexed in PubMed, published in European journal of endocrinology (1998).
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews (2026)
Peer-reviewed article indexed in PubMed, published in Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews (2026).
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians — The American journal of sports medicine (2026)
Peer-reviewed article indexed in PubMed, published in The American journal of sports medicine (2026).
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — Sports medicine (Auckland, N.Z.) (2026)
Peer-reviewed article indexed in PubMed, published in Sports medicine (Auckland, N.Z.) (2026).
- Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats — Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Resear (1999)
Peer-reviewed article indexed in PubMed, published in Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society (1999).
- The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism — Physiology & behavior (2024)
Peer-reviewed article indexed in PubMed, published in Physiology & behavior (2024).
- The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus — Animal reproduction science (2024)
Peer-reviewed article indexed in PubMed, published in Animal reproduction science (2024).
- Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers — Pharmaceutical research (1999)
Peer-reviewed article indexed in PubMed, published in Pharmaceutical research (1999).
Indexed studies3 human-evidence of 3
- Early-phase human work on ipamorelin — Human — controlled trial
Placeholder seed record. A small early-phase human literature exists. The development programme was not carried forward to approval, and the listed work does not establish a durable clinical effect.
- Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients — Human — controlled trial, 2014
Postoperative ileus is a significant clinical challenge lacking effective management strategies. Ghrelin-receptor stimulation has promotility effects in the upper and lower gastrointestinal tract. This proof-of-concept, phase 2, randomized study evaluated the safety and efficacy of the ghrelin-receptor agonist ipamorelin in the treatment of postoperative ileus following abdominal surgery (ClinicalTrials.gov NCT00672074). The design was a multicenter, double-blind, placebo-con…
- Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers — Human — controlled trial, 1999
To examine the pharmacokinetics (PK) and pharmacodynamics (PD) of ipamorelin, a growth hormone (GH) releasing peptide, in healthy volunteers. A trial was conducted with a dose escalation design comprising 5 different infusion rates (4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg over 15 minutes) with eight healthy male subjects at each dose level. Concentrations of ipamorelin and growth hormone were measured. The PK parameters showed dose-proportionality, with a short terminal …
Evidence digest
What the research on ipamorelin actually shows
Ipamorelin has a small early-phase human literature that was not carried forward to approval. Development programmes are abandoned for many reasons — commercial, strategic and scientific — and the published record does not establish a durable clinical effect. A discontinued programme is not evidence of efficacy, and it is not evidence of harm either; it is an absence of conclusion.
4 things the literature does not establish →
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.
Vendor comparison
| Vendor | Score here | Price / mg | Certificates | Mean purity | Label deviation | Get it |
|---|---|---|---|---|---|---|
| Next Gen PeptidesISO/IEC 17025 | 93.897% | $2.80 (37%) | 2 | 99.6% | 55.7% | |
| CuroISO/IEC 17025 | 93.877% | — | 2 | 99.8% | 6.2% | |
| Polaris PeptidesISO/IEC 17025 | 93.877% | — | 1 | 99.7% | 0.7% | |
| Amino ClubISO/IEC 17025 | 90.495% | — | 0 | — | — | |
| Ascend ScienceISO/IEC 17025 | 90.291% | — | 1 | 99.5% | 9.8% | |
| PeptidePlugs | 89.790% | $3.50 (47%) | 2 | 99.8% | 9.2% | |
| Hydro Research PeptidesISO/IEC 17025 | 88.289% | — | 1 | 99.9% | 13.0% | |
| Prime PeptidesISO/IEC 17025 | 87.180% | — | 1 | 99.8% | 4.4% | |
| Northline LabsISO/IEC 17025 | 85.393% | $7.50 (100%) | 1 | 99.2% | 2.1% | |
| American PeptidesISO/IEC 17025 | 85.2100% | $8.00 (107%) | 1 | 99.9% | 12.8% | |
| NeuroLabs Research | 85.186% | $4.50 (60%) | 1 | 99.5% | 6.6% | |
| Protide Health | 83.994% | $7.50 (100%) | 0 | — | — | |
| ZC Labs | 82.984% | $5.00 (67%) | 3 | 99.7% | 8.3% | |
| Good Science Bio | 79.275% | $4.50 (60%) | 0 | — | — | |
| Simple Peptide | 77.389% | $10.00 (133%) | 2 | 99.9% | 14.4% | |
| Licensed Peptides | 7789% | — | 1 | 99.8% | 7.5% | |
| BioLongevity Labs | 74.974% | $6.50 (87%) | 0 | — | — | |
| Modern AminosISO/IEC 17025 | 74100% | $15.00 (200%) | 2 | 99.9% | 5.9% | |
| Extreme Peptides | 73.682% | $5.36 (72%) | 1 | 99.9% | 0.0% | |
| Koi Peptides | 73.194% | $10.00 (133%) | 0 | — | — | |
| Ascension Peptides | 71.486% | $10.00 (133%) | 3 | 99.8% | 0.2% | |
| Mile High Compounds | 68.194% | $6.00 (80%) | 0 | — | — | |
| Eternal Peptides | 6865% | $6.75 (90%) | 0 | — | — | |
| GenX Peptides | 64.868% | $8.75 (117%) | 0 | — | — | |
| Evolve Peptides | 55.967% | $11.29 (151%) | 0 | — | — | |
| Sports Technology Labs | 54.974% | $25.80 (250%) | 0 | — | — |
Certificate records
| Vendor | Lot | Tested | Lab | Labeled | Assayed | Discrepancy | Purity | Source |
|---|---|---|---|---|---|---|---|---|
| ZC Labs | ZCLa2608110024 | Freedom Diagnostics Testing | 10 mg | 9.76 mg | 2.4% | 99.8% | Vendor-published | |
| Ascend Science | AS-CP10-2 | Kovera Labs and/or ILS Labs | 10 mg | 10.98 mg | 9.8% | 99.5% | Vendor-published | |
| PeptidePlugs | 103-10-ZB | Freedom Diagnostics Testing | 10 mg | 11.15 mg | 11.5% | 99.8% | Vendor-published | |
| ZC Labs | ZCLa2607200288 | Freedom Diagnostics Testing | 10 mg | 8.95 mg | 10.5% | 99.6% | Vendor-published | |
| NeuroLabs Research | NL01-IPA10R | Analysis FreedomDiagnostics | 10 mg | 9.34 mg | 6.6% | 99.5% | Vendor-published | |
| Curo | IPA10ZO626 | BTLabs | 10 mg | 10.04 mg | 0.4% | 99.9% | Vendor-published | |
| ZC Labs | ZCLa2606260480 | Freedom Diagnostics Testing | 10 mg | 11.21 mg | 12.1% | 99.8% | Vendor-published | |
| Modern Aminos | BX-P-M9Q4 | Analysis FreedomDiagnostics | 10 mg | 9.21 mg | 7.9% | 99.9% | Vendor-published | |
| PeptidePlugs | 142-04-DK | Freedom Diagnostics Testing | 10 mg | 9.31 mg | 6.9% | 99.8% | Vendor-published | |
| Modern Aminos | BX-P-L7T0 | Analysis FreedomDiagnostics | 10 mg | 9.61 mg | 3.9% | 99.9% | Vendor-published | |
| Simple Peptide | IPA10-062026-1 | Analysis FreedomDiagnostics | 10 mg | 11.61 mg | 16.1% | 99.8% | Vendor-published | |
| Simple Peptide | IPCJ20-052026-4 | Analysis FreedomDiagnostics | 10 mg | 11.27 mg | 12.7% | 99.9% | Vendor-published | |
| Curo | IPA05SR526 | BTLabs | 5 mg | 5.6 mg | 12.0% | 99.8% | Vendor-published | |
| Next Gen Peptides | IPA10-01 | ILS Laboratories | 10 mg | 10.22 mg | 2.2% | 99.6% | Vendor-published | |
| Northline Labs | NLL-5192680 | Horizon Analytical | 10 mg | 9.79 mg | 2.1% | 99.2% | Vendor-published | |
| Hydro Research Peptides | HR-2026-3915 | ILS Laboratories | 5 mg | 5.65 mg | 13.0% | 99.9% | Vendor-published | |
| Prime Peptides | 3162026IPA | Bioviridian Inc. | 10 mg | 10.44 mg | 4.4% | 99.8% | Vendor-published | |
| Next Gen Peptides | CJPA10-03 | ILS Laboratories | 5 mg | 10.46 mg | 109.2% | 99.6% | Vendor-published | |
| blank-peptides | 665394 | Freedom Diagnostics | 10 mg | 10 mg | 0.0% | 99.0% | Vendor-published | |
| American Peptides | IPA5-0318 | American Peptides | 5 mg | 5.64 mg | 12.8% | 99.9% | Vendor-published | |
| Ascension Peptides | 59-03260429 | MZ Biolabs | 13.14 mg | 13.08 mg | 0.5% | 99.6% | Vendor-published | |
| Extreme Peptides | EXT-CJIP-00008 | Richard Sylvester MD | 5.22 mg | 5.22 mg | 0.0% | 99.9% | Vendor-published | |
| Licensed Peptides | IPAMOR-01 | Vanguard Laboratory | 10 mg | 10.75 mg | 7.5% | 99.8% | Vendor-published | |
| Ascension Peptides | 06-01260229 | MZ Biolabs | 12.73 mg | 12.73 mg | 0.0% | 99.9% | Vendor-published | |
| Polaris Peptides | SPL-2028 | TrustPointe Analytics LLC | 5 mg | 5.03 mg | 0.7% | 99.7% | Vendor-published | |
| Ascension Peptides | 2024-06-03 | MZ Biolabs | 5 mg | 4.99 mg | 0.2% | 99.8% | Vendor-published |